NewAmsterdam Pharma (NASDAQ:NAMS) Earns Buy Rating from Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of NewAmsterdam Pharma (NASDAQ:NAMS) in a report published on Thursday,Benzinga reports. They currently have a $36.00 target price on the stock.

NAMS has been the topic of a number of other reports. Royal Bank of Canada reaffirmed an “outperform” rating and set a $31.00 price objective on shares of NewAmsterdam Pharma in a research report on Thursday, September 5th. Piper Sandler restated an “overweight” rating and set a $37.00 price target on shares of NewAmsterdam Pharma in a report on Monday, September 23rd. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, NewAmsterdam Pharma has an average rating of “Buy” and an average price target of $33.80.

NewAmsterdam Pharma Trading Down 0.3 %

NASDAQ NAMS traded down $0.06 during trading on Thursday, reaching $20.06. 220,548 shares of the company’s stock were exchanged, compared to its average volume of 291,496. NewAmsterdam Pharma has a fifty-two week low of $8.90 and a fifty-two week high of $26.35. The company’s fifty day simple moving average is $18.98 and its 200-day simple moving average is $18.63.

Insider Transactions at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, major shareholder Nap B.V. Forgrowth sold 8,530 shares of the company’s stock in a transaction that occurred on Friday, November 15th. The stock was sold at an average price of $25.02, for a total transaction of $213,420.60. Following the completion of the sale, the insider now owns 11,812,033 shares of the company’s stock, valued at $295,537,065.66. This represents a 0.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Louise Frederika Kooij sold 45,000 shares of the stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $15.72, for a total value of $707,400.00. The disclosure for this sale can be found here. Insiders have sold a total of 86,803 shares of company stock worth $1,755,307 in the last 90 days. 19.50% of the stock is owned by insiders.

Institutional Trading of NewAmsterdam Pharma

Several large investors have recently modified their holdings of the company. Banque Cantonale Vaudoise bought a new position in NewAmsterdam Pharma in the 2nd quarter worth $38,000. Quarry LP lifted its position in shares of NewAmsterdam Pharma by 2,469.2% during the 3rd quarter. Quarry LP now owns 6,500 shares of the company’s stock worth $108,000 after purchasing an additional 6,247 shares during the last quarter. Barclays PLC lifted its position in shares of NewAmsterdam Pharma by 1,813.4% during the 3rd quarter. Barclays PLC now owns 7,596 shares of the company’s stock worth $126,000 after purchasing an additional 7,199 shares during the last quarter. Bellevue Group AG bought a new stake in NewAmsterdam Pharma during the 3rd quarter valued at approximately $128,000. Finally, Rosalind Advisors Inc. acquired a new stake in NewAmsterdam Pharma in the 2nd quarter valued at approximately $194,000. 89.89% of the stock is owned by institutional investors.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.